Europe
As a result, the company will cut 300 jobs, primarily in Massachusetts and Connecticut.
A look at the lucky drugs that have been hailed a breakthrough by the FDA.
The offers underline Novo Nordisk’s interest in expanding beyond diabetes and into the rare diseases market.
Medtronic’s building permit for the new facility is valued at $900,000, with the listed architect as Thoda & Associates.
The company’s newly-acquired funds will specifically support a new R&D facility located in Bavaria.
Shares of TiGenix shot up more than 72 percent in pre-market trading after the deal was announced.
Ablynx today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday 8 January 2018 at 09:30 a.m. Pacific Standard Time (06:30 p.m. Central European Time).
A Novartis drug approved as a second-line treatment for a blood disorder snagged the FDA’s Breakthrough Therapy Designation as a first-line defense.
Allergan will cut about 5 percent of its workforce, as the company looks to cut costs due to increased pipeline competition and loss of exclusivity on some products.
The company said the Breakthrough Therapy Designation is based on positive results from the Phase III MONALEESA-7 trial.
PRESS RELEASES